iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$16.16 USD
-0.05 (-0.31%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.15 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
iTeos Therapeutics, Inc. [ITOS]
Reports for Purchase
Showing records 81 - 100 ( 112 total )
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Undervalued Name With a Robust Balance Sheet; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Know Who''s on 1st, What''s on 2nd, but We Don''t Know ITOS''s 3rd Candidate
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
GSK Collaboration Validates EOS-448; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Inupadenant Monotherapy Continues to Show Clinical Benefit; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EOS-850 Hints at Potential Patient Selection
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Inupadenant Data Update Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
?''448: Top TIGIT to Twosomes, Taking on Titans
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Tickle of Activity with anti-TIGIT Antibody
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Will ITOS Show Best-In-Class Anti-TIGIT Monotherapy Data at AACR?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D